These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10077027)

  • 41. Overview of nanoparticle use in cancer imaging.
    Islam T; Harisinghani MG
    Cancer Biomark; 2009; 5(2):61-7. PubMed ID: 19414922
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MR imaging with i.v. superparamagnetic iron oxide: efficacy in the detection of focal hepatic lesions.
    Winter TC; Freeny PC; Nghiem HV; Mack LA; Patten RM; Thomas CR; Elliott S
    AJR Am J Roentgenol; 1993 Dec; 161(6):1191-8. PubMed ID: 8249724
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Superparamagnetic iron oxide particle-enhanced hepatic MRI: differentiation of hepatic lesions using dual echo field echo sequences without obtaining precontrast images.
    Kuwatsuru R; Ito S; Akamatsu M; Maehara T
    Acad Radiol; 2002 Aug; 9 Suppl 2():S473-5. PubMed ID: 12188312
    [No Abstract]   [Full Text] [Related]  

  • 44. MR imaging of mediastinal lymph nodes: evaluation using a superparamagnetic contrast agent.
    Pannu HK; Wang KP; Borman TL; Bluemke DA
    J Magn Reson Imaging; 2000 Dec; 12(6):899-904. PubMed ID: 11105028
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical evaluation of ultrasmall superparamagnetic iron oxide particles for liver imaging.
    Saini S; Edelman RR; Li W; Petersein J; Hahn PF
    Acad Radiol; 1996 Aug; 3 Suppl 2():S409-12. PubMed ID: 8796616
    [No Abstract]   [Full Text] [Related]  

  • 46. Magnetic resonance imaging of experimental atherosclerotic plaque: comparison of two ultrasmall superparamagnetic particles of iron oxide.
    Herborn CU; Vogt FM; Lauenstein TC; Dirsch O; Corot C; Robert P; Ruehm SG
    J Magn Reson Imaging; 2006 Aug; 24(2):388-93. PubMed ID: 16791857
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical results with Resovist: a phase 2 clinical trial.
    Reimer P; Rummeny EJ; Daldrup HE; Balzer T; Tombach B; Berns T; Peters PE
    Radiology; 1995 May; 195(2):489-96. PubMed ID: 7724772
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: a potential new sign for characterization of liver lesions.
    Mergo PJ; Helmberger T; Nicolas AI; Ros PR
    AJR Am J Roentgenol; 1996 Feb; 166(2):379-84. PubMed ID: 8553952
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours.
    Neuwelt EA; Várallyay P; Bagó AG; Muldoon LL; Nesbit G; Nixon R
    Neuropathol Appl Neurobiol; 2004 Oct; 30(5):456-71. PubMed ID: 15488022
    [TBL] [Abstract][Full Text] [Related]  

  • 50. USPIO-enhanced magnetic resonance imaging for nodal staging in patients with head and neck cancer.
    Curvo-Semedo L; Diniz M; Miguéis J; Julião MJ; Martins P; Pinto A; Caseiro-Alves F
    J Magn Reson Imaging; 2006 Jul; 24(1):123-31. PubMed ID: 16755542
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety of ferucarbotran in MR imaging of the liver: a pre- and postexamination questionnaire-based multicenter investigation.
    Onishi H; Murakami T; Kim T; Hori M; Hirohashi S; Matsuki M; Narumi Y; Imai Y; Sakurai K; Nakamura H
    J Magn Reson Imaging; 2009 Jan; 29(1):106-11. PubMed ID: 19097079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil.
    Jung CW; Jacobs P
    Magn Reson Imaging; 1995; 13(5):661-74. PubMed ID: 8569441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. European clinical experience with Endorem. A new contrast agent for liver MRI in 1000 patients.
    Chachuat A; Bonnemain B
    Radiologe; 1995 Nov; 35(11 Suppl 2):S274-6. PubMed ID: 8588035
    [No Abstract]   [Full Text] [Related]  

  • 54. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization?
    Harisinghani MG; Saksena MA; Hahn PF; King B; Kim J; Torabi MT; Weissleder R
    AJR Am J Roentgenol; 2006 Jan; 186(1):144-8. PubMed ID: 16357394
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differences in predominant enhancement mechanisms of superparamagnetic iron oxide and ultrasmall superparamagnetic iron oxide for contrast-enhanced portal magnetic resonance angiography. Preliminary results of an animal study original investigation.
    Knollmann FD; Böck JC; Rautenberg K; Beier J; Ebert W; Felix R
    Invest Radiol; 1998 Sep; 33(9):637-43. PubMed ID: 9766048
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biodistribution and toxicity of MR imaging contrast media.
    Oksendal AN; Hals PA
    J Magn Reson Imaging; 1993; 3(1):157-65. PubMed ID: 8428083
    [No Abstract]   [Full Text] [Related]  

  • 57. Characterization of focal liver lesions with superparamagnetic iron oxide-enhanced MR imaging: value of distributional phase T1-weighted imaging.
    Lee JM; Kim CS; Youk JH; Lee MS
    Korean J Radiol; 2003; 4(1):9-18. PubMed ID: 12679629
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ferrimagnetic susceptibility contrast agents.
    Bach-Gansmo T
    Acta Radiol Suppl; 1993; 387():1-30. PubMed ID: 8390776
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
    Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
    Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging.
    Saksena MA; Saokar A; Harisinghani MG
    Eur J Radiol; 2006 Jun; 58(3):367-74. PubMed ID: 16472955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.